JH021 drug trial for advanced lung or solid tumors
Part of Cancer clinical trials.
This early-stage trial tests a new drug called JH021 in people with advanced cancer that has stopped responding to standard treatments. The drug may help patients with certain lung cancers (NSCLC with specific EGFR mutations) or other solid tumors grow back after other therapies have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Confirmed cancer that has progressed despite previous treatment(s), or standard treatments are unavailable, not tolerated, or refused
- At least one measurable tumor visible on imaging scans
- Good overall health status (able to do light activity; ECOG score 0–1)
- Expected to live at least 12 weeks
- Adequate blood cell counts, liver, kidney, and heart function (confirmed by recent lab tests)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new medicine called JMT106 for people with advanced solid tumors (cancers that have spread or can't be removed). It's for patients whose cancer has not responded to or can't use other treatments, and who have not had a therapy targeting a specific protein (GPC3) before.
This Phase 1 trial tests a new medicine (HG381) in people with advanced solid tumors to see how safe it is and how it works in the body. It may help if standard treatments have already stopped working or aren’t possible for you.
This trial is testing a new drug (HC010) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe, how it works in the body, and whether it can shrink tumors.
This early-phase trial tests a once-daily tablet (HJ-004-02) for people with a specific type of lung cancer that has an EGFR mutation. It aims to see if the drug is safe and if it can shrink tumors when other treatments have stopped working.
This trial tests a new drug, JSKN021, for people with advanced solid tumors that have not responded to standard treatments, are not tolerated to them, or have no standard options. The goal is to see if the drug is safe and effective in treating these cancers.
This trial tests a new drug called JY016 for people with solid tumors that have the EGFR protein. It is for patients whose cancer has not responded to other treatments. The goal is to see if JY016 can shrink tumors or slow cancer growth.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.